Do We Still Need Aspirin in Coronary Artery Disease?

Do We Still Need Aspirin in Coronary Artery Disease?

Aspirin has for some time been used as a first-line treatment for acute coronary syndromes, including ST-elevation myocardial infarction, for secondary prevention of established coronary disease, and for primary prevention in patients at risk of coronary artery disease. Although aspirin has been in...

Full description

Bibliographic Details
Main Authors:	Muhammad Haisum Maqsood, Glenn N. Levine, Neal D. Kleiman, David Hasdai, Barry F. Uretsky, Yochai Birnbaum
Format:	Article
Language:	English
Published:	MDPI AG 2023-12-01
Series:	Journal of Clinical Medicine
Subjects:	acute coronary syndrome aspirin clopidogrel P2Y12 inhibitors percutaneous coronary intervention primary prevention
Online Access:	https://www.mdpi.com/2077-0383/12/24/7534

Similar Items

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
by: V. A. Sulimov, et al.
Published: (2015-12-01)

Upper gastrointestinal bleed in a post menopausal woman due to combination of high first dose aspirin and clopidogrel prescribed for acute coronary syndrome
by: Vishal R Tandon, et al.
Published: (2015-01-01)

Efficacy and safety of clopidogrel versus aspirin monotherapy for secondary prevention in patients with coronary artery disease: a meta-analysis
by: Di Liu, et al.
Published: (2023-10-01)

Prasugrel
by: Gianluca Airoldi, et al.
Published: (2013-04-01)

Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery
by: Jianyu Qu, et al.
Published: (2021-06-01)

Association of Clinical Outcomes With Sex in Patients Receiving Chronic Maintenance Antiplatelet Monotherapy After Percutaneous Coronary Intervention: A Post Hoc Gender Analysis of the HOST‐EXAM Study
by: Eun‐Seok Shin, et al.
Published: (2023-04-01)

Aspirin after PCI: in the twilight of its years?
by: William A. E. Parker
Published: (2020-10-01)

A single center experience of rapid aspirin desensitization in acute coronary syndrome patients
by: Christoforos Vlachos, et al.
Published: (2022-03-01)

Comparison of administration of clopidogrel with aspirin versus aspirin alone in prevention of secondary stroke after transient ischemic attack
by: Mojtaba Khazaei, et al.
Published: (2019-03-01)

Increased blood product use among coronary artery bypass patients prescribed preoperative aspirin and clopidogrel
by: Alexander Kurian S, et al.
Published: (2003-05-01)

Real-world experience of clinical management with antiplatelet and lipid-lowering therapy in post acute coronary syndrome patients in Indian setting
by: M S Hiremath, et al.
Published: (2021-01-01)

Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy
by: Barry W. Hennigan, et al.
Published: (2022-01-01)

Pharmacodynamic effects of a new fixed-dose clopidogrel–aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial
by: Jin-Sin Koh, et al.
Published: (2017-02-01)

Vorapaxar
by: Gianluca Airoldi, et al.
Published: (2013-04-01)

CLOPIDOGREL FOR SELECTIVE MYOCARDIAL REVASCULARIZATION
by: N. V. Teplova
Published: (2016-03-01)

P2Y12 Inhibitor vs Aspirin Monotherapy Following Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: An Updated Meta-Analysis
by: Tong Gao, et al.
Published: (2023-10-01)

Comparison of ESC and ACCF/AHA Guidelines for Oral Antiplatelet Treatment in the Management of Patients with Acute Coronary Syndrome
by: Ayhan Sarıtaş, et al.
Published: (2016-09-01)

Efficacy and safety of switching from ticagrelor to clopidogrel during the early and late phase in acute coronary syndrome patients after percutaneous coronary intervention
by: Chenggang Wang, et al.
Published: (2020-04-01)

Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients
by: J.F.M. Marchini, et al.

Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registry
by: Chunfeng Dai, et al.
Published: (2024-04-01)

Clopidogrel Adherence to AHA/ACC Guideline in Patients with Open Heart Surgery in a Tertiary Heart Center
by: Naser Safaie, et al.
Published: (2019-09-01)

Efficacy and safety of concomitant use of proton pump inhibitors with aspirin-clopidogrel dual antiplatelet therapy in coronary heart disease: A systematic review and meta-analysis
by: Xiaofeng Luo, et al.
Published: (2023-01-01)

Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention
by: Kreutz RP, et al.
Published: (2016-06-01)

ASPIRIN IN THE PREVENTION OF ATHEROTHROMBOSIS AND CORONARY HEART DISEASE
by: M. G. Bubnova
Published: (2010-08-01)

Comparison Between Aspirin and Clopidogrel in Secondary Stroke Prevention Based on Real‐World Data
by: Nai‐Fang Chi, et al.
Published: (2018-10-01)

Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Acute Coronary Syndrome: A Comprehensive Meta-Analysis
by: Mengyi Sun, et al.
Published: (2022-01-01)

Comparison of clopidogrel and ticagrelor in treating acute coronary syndrome undergoing PCI: A systematic review and meta-analysis
by: Jing Yang, et al.
Published: (2024-03-01)

Short-term clinical outcomes of ticagrelor versus clopidogrel after percutaneous coronary intervention in patients with myocardial infarction: A randomized clinical trial study
by: Salman Nikfarjam, et al.
Published: (2023-01-01)

EVALUATION OF ASPIRIN USAGE SAFETY IN CORONARY BYPASS SURGERY
by: A. M. Chernyavsky, et al.
Published: (2017-10-01)

Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis
by: Fan ZG, et al.
Published: (2019-02-01)

Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial
by: Hyun-Woong Park, et al.
Published: (2021-06-01)

Early Discontinuation of P2Y12 Antagonists and Adverse Clinical Events Post–Percutaneous Coronary Intervention: A Hospital and Primary Care Linked Cohort
by: Daniel E. Harris, et al.
Published: (2019-11-01)

Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV
by: Emanuela Marcantoni, PhD, et al.
Published: (2022-11-01)

THE EFFECTIVENESS OF CLOPIDOGREL AS AN ANTITHROMBOTIC COMPARED TO TICLOPIDINE AND ASPIRIN (META-ANALYSIS)
by: Titien Siwi Hartayu, et al.
Published: (2017-05-01)

The association between aspirin resistance and extent and severity of coronary atherosclerosis
by: Serkan Kahraman, et al.
Published: (2018-12-01)

ANTIAGGREGANT THERAPY AND REDUCTION OF HIGH RESIDUAL PLATELET REACTIVITY
by: N. A. Mazur, et al.
Published: (2012-08-01)

Thrombelastographic haemostatic status and antiplatelet therapy after coronary artery bypass surgery (TEG-CABG trial): assessing and monitoring the antithrombotic effect of clopidogrel and aspirin versus aspirin alone in hypercoagulable patients: study protocol for a randomized controlled trial
by: Rafiq Sulman, et al.
Published: (2012-04-01)

Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice?
by: T. M. Uskach, et al.
Published: (2020-12-01)

Choice of dual antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention
by: A. N. Golosova, et al.
Published: (2020-08-01)

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: What is new?
by: Zeki Öngen
Published: (2018-01-01)